Telix Pharmaceuticals Ltd (ASX: TLX) shares are pushing higher on Friday.
At the time of writing, they are up 4% to $14.17 after a major regulatory update in the United States.
The radiopharmaceuticals company announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA) for TLX101-Px (Pixclara), which is a potential imaging agent for brain cancer.
So, is this a buying opportunity for investors?
Image source: Getty Images
A major milestone, but not the finish line
The US FDA acceptance is a significant step forward for Telix.
According to the company, the regulator has now assigned a PDUFA goal date of 11 September, which sets a clear timeline for a potential approval decision.
This is important because it moves the product further along the regulatory pathway and reduces uncertainty around timing.
However, it is worth noting that acceptance is not approval.
There is still a review process ahead, and while the outlook may be positive, regulatory risk remains. Investors should be mindful that outcomes are not guaranteed.
Strong broker support adds confidence
Despite the risks, brokers appear optimistic about Telix's outlook.
UBS recently placed a buy rating on the company with a $31.00 price target, suggesting that Telix shares could more than double in value from current levels.
Bell Potter is also positive and highlighted the importance of this regulatory catalyst. Earlier this week, it said:
The major short term catalyst is the regulatory update for TLX101 (Pixclara). The company has re-submitted the NDA and is now awaiting confirmation that the resubmission is accepted for review (which is a virtual certainty) at which time the FDA will also publish a PDUFA date. We expect a review period of 6 to 8 months, hence earliest possible approval is 4Q CY26.
The broker also pointed to broader progress across the pipeline. It adds:
The company continues to make good progress on multiple pipeline products. Short term news flow includes acceptance by the FDA of the resubmitted NDA for Pixclara and the amendment to the IND for TLX591 (prostate cancer Tx). We maintain our Buy rating. FY26 EBITDA is increased by ~US$21m to US$55.3m.
This combination of near-term catalysts and improving earnings expectations is helping support the investment case according to the broker.
So much so, it put a buy rating and $19.00 price target on its shares. This implies potential upside of 34% for investors from current levels.
Should you buy Telix shares?
The FDA acceptance is a meaningful milestone that brings Telix closer to unlocking additional value from its pipeline. Combined with bullish brokers and strong momentum across its broader portfolio, the outlook appears encouraging.
However, investors should remember that regulatory approvals are never guaranteed, and volatility is likely along the way. Nevertheless, this could be a good time to consider a patient investment in the radiopharmaceuticals company.
